Role of Selective Cyclooxygenase-2 Inhibitor in Acute Pancreatitis
- Conditions
- Health Condition 1: K85- Acute pancreatitis
- Registration Number
- CTRI/2020/10/028188
- Lead Sponsor
- Dr Pramod Kumar Garg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. Acute pancreatitis as defined by revised Atlanta classification.
2. The time interval from the onset of symptoms to presentation should be less than 7 days.
3. Systemic inflammatory response syndrome (SIRS) persisting for more than 24 hours.
1. Age less than 18 years or more than 70 years
2. Patients with Grade 2 or more organ failure as per Modified Marshallâ??s criteria.
3. Patients with a serum creatinine >1.4 mg/dl
4. Active or past history of GI bleeding or peptic ulcer disease
5. Patients with significant co-morbidity such as coronary artery disease, chronic kidney disease, cirrhosis, chronic obstructive airway disease, inflammatory bowel disease, and congestive heart failure or malignancy.
6. Patients who have history of bronchospasm, urticaria, angioneurotic edema or other allergic reactions to COX-2 inhibitors
7. Patients with evidence of chronic pancreatitis
8. Pregnancy and breast feeding
9. Failure to give consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Frequency of occurrence of persistent organ failure <br/ ><br>2. Deterioration in OF score by one grade <br/ ><br>Timepoint: Four weeks or discharge
- Secondary Outcome Measures
Name Time Method 1. Change in APACHE II and SIRS scores <br/ ><br>2. Duration of ICU stay and hospital stay <br/ ><br>3. Reduction in the need for rescue analgesia <br/ ><br>4. Reduction in level of CRP and inflammatory cytokines <br/ ><br>5. Mortality within 30 days. <br/ ><br>6. Adverse event such as gastrointestinal bleed, hypersensitivity reaction, renal impairment <br/ ><br>Timepoint: Four weeks or discharge